[开放获取]    特殊部位银屑病系统治疗临床研究进展

doi:10.35541/cjd.20230190

Abstract

Abstract: 【Abstract】 Psoriasis in special areas affects the scalp, nails, palms/soles, and genital sites, and inadequate diagnosis and treatment, as well as poor response to conventional therapies, remain problems in clinical practice. The review summarizes and updates clinical evidence on the efficacy and safety of conventional systemic agents, biologics, and oral small-molecule targeted agents for the treatment of psoriasis in special areas, providing a reference for clinicians to individualize therapies for their patients.

Key words: Psoriasis, Psoriasis in special areas, Tumor necrosis factor α inhibitors, Interleukin-17 inhibitors, Interleukin-23 inhibitors, Phosphodiesterase 4 inhibitors, Tyrosine kinase 2 inhibitors

Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas[J]. Chinese Journal of Dermatology,2024,e20230190. doi:10.35541/cjd.20230190

References ［55］

［1］	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识［J］. 中华皮肤科杂志, 2023,56（3）:191⁃203. doi: 10.35541/cjd.20220652.
［2］	Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult⁃to⁃treat areas: scalp, nail, palmoplantar and genital psoriasis［J］. J Clin Med, 2022,11（9）:2631. doi: 10.3390/jcm11092631.
［3］	Lanna C, Galluzzi C, Zangrilli A, et al. Psoriasis in difficult to treat areas: treatment role in improving health⁃related quality of life and perception of the disease stigma［J］. J Dermatolog Treat, 2022,33（1）:531⁃534. doi: 10.1080/09546634.2020.1770175.
［4］	Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard⁃to⁃treat body locations: data from the Danish skin cohort［J］. BMC Dermatol, 2020,20（1）:3. doi: 10.1186/s12895⁃020⁃00099⁃7.
［5］	Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council［J］. J Am Acad Dermatol, 2020,82（1）:117⁃122. doi: 10.1016/j.jaad.2019.08.026.
［6］	Ghafoor R, Patil A, Yamauchi P, et al. Treatment of scalp psoriasis［J］. J Drugs Dermatol, 2022,21（8）:833⁃837. doi: 10. 36849/JDD.6498.
［7］	Camela E, Ocampo⁃Garza S S, Cinelli E, et al. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review［J］. Dermatol Ther, 2021,34（2）:e14857. doi: 10.1111/dth.14857.
［8］	Mosca M, Hong J, Hadeler E, et al. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management［J］. Dermatol Ther（Heidelb）, 2021,11（3）:769⁃797. doi: 10.1007/s13555⁃021⁃00521⁃z.
［9］	Thaçi D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study［J］. J Eur Acad Dermatol Venereol, 2015,29（2）:353⁃360. doi: 10.1111/jdv.12553.
［10］	Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate⁃to⁃severe psoriasis with scalp involvement: results from three phase 3 trials（UNCOVER⁃1, UNCOVER⁃2, UNCOVER⁃3）［J］. J Dermatolog Treat, 2017,28（4）:282⁃287. doi: 10.1080/09546634.2016.1249820.
［11］	Kamata M, Tada Y. Safety of biologics in psoriasis［J］. J Dermatol, 2018,45（3）:279⁃286. doi: 10.1111/1346⁃8138.14096.
［12］	Ten Bergen LL, Petrovic A, Krogh Aarebrot A, et al. The TNF/IL⁃23/IL⁃17 axis⁃head⁃to⁃head trials comparing different biologics in psoriasis treatment［J］. Scand J Immunol, 2020,92（4）:e12946. doi: 10.1111/sji.12946.
［13］	Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate⁃to⁃severe scalp psoriasis: results of a 24⁃week, randomized, double⁃blind, placebo⁃controlled phase 3b study ［J］. J Am Acad Dermatol, 2017,77（4）:667⁃674. doi: 10.1016/j.jaad.2017.05.033.
［14］	Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials［J］. J Dermatolog Treat, 2022,33（1）:261⁃265. doi: 10.1080/ 09546634.2020.1749546.
［15］	Merola JF, Warren RB, Han G. Bimekizumab response maintenance in high⁃impact areas in patients with moderate to severe plaque psoriasis: pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials ［J］. J Eur Acad Dermatol, 2022,87（3, Supplement）:AB24. doi: 10.1016/j.jaad.2022.06.131.
［16］	George M. Selected poster abstracts from MauiDerm 2021 for dermatologists［J］. J Clin Aesthet Dermatol, 2021,14（5 Suppl 1）:S8⁃S30.
［17］	Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials［J］. JAMA Dermatol, 2018,154（6）:676⁃683. doi: 10.1001/jamadermatol.2018.0793.
［18］	Menter M A, Murakawa G J, Glover H, et al. Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 RESURFACE 1 study［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:e803⁃e805. doi: 10.1111/jdv. 16648.
［19］	Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab（LY3074828） in the treatment of moderate⁃to⁃severe plaque psoriasis: results from a randomized phase II study［J］. Br J Dermatol, 2019,181（1）:88⁃95. doi: 10.1111/bjd.17628.
［20］	Gerdes S, Bräu B, Hoffmann M, et al. Real⁃world effectiveness of guselkumab in patients with psoriasis: health⁃related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial［J］. J Dermatol, 2021,48（12）:1854⁃1862. doi: 10.1111/1346⁃8138.16128.
［21］	Papadimitriou I, Bakirtzi K, Katoulis A, et al. Scalp psoriasis and biologic agents: a review［J］. Skin Appendage Disord, 2021,7（6）:439⁃448. doi: 10.1159/000517806.
［22］	Bai F, Li GG, Liu Q, et al. Short⁃term efficacy and safety of IL⁃17, IL⁃12/23, and IL⁃23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta⁃analysis of randomized controlled trials［J］. J Immunol Res, 2019,2019:2546161. doi: 10.1155/2019/2546161.
［23］	Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phase Ⅲ randomized, controlled trials（ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016,74（1）:134⁃142. doi: 10.1016/j.jaad.2015.09.001.
［24］	Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate⁃to⁃severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study［J］. Br J Dermatol, 2021,185（4）:840⁃842. doi: 10.1111/bjd.20083.
［25］	Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, placebo⁃controlled phase 3 POETYK PSO⁃1 trial［J］. J Am Acad Dermatol, 2023,88（1）:29⁃39. doi: 10.1016/j.jaad.2022.07.002.
［26］	Strober B, Thaci D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial［J］. J Am Acad Dermatol, 2023,88（1）:40⁃51. doi: 10.1016/j.jaad.2022.08.061.
［27］	Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO⁃1 and PSO⁃2 trials［A］; proceedings of the FC PANP 22 Dermatology Conference［C］, Scottsdale, AZ, US, June 3⁃5, 2022.
［28］	Kaeley GS, Eder L, Aydin SZ, et al. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs［J］. J Rheumatol, 2021,48（8）:1208⁃1220. doi: 10.3899/jrheum.201471.
［29］	Krajewska⁃Wlodarczyk M, Zuber Z, Owczarczyk⁃Saczonek A. Ultrasound evaluation of the effectiveness of the use of acitretin in the treatment of nail psoriasis［J］. J Clin Med, 2021,10（10）:2122. doi: 10.3390/jcm10102122.
［30］	Augustin M, Landeck L, Diemert S, et al. Long⁃term treatment with dimethyl fumarate for plaque psoriasis in routine practice: good overall effectiveness and positive effect on impactful areas［J］. Dermatol Ther（Heidelb）, 2022,12（5）:1121⁃1131. doi: 10. 1007/s13555⁃022⁃00714⁃0.
［31］	Mrowietz U, Kircik L, Reich K, et al. Tepilamide fumarate（PPC⁃06） extended release tablets in patients with moderate⁃to⁃severe plaque psoriasis: safety and efficacy results from the randomized, double⁃blind, placebo⁃controlled AFFIRM study［J］. J Clin Aesthet Dermatol, 2022,15（1）:53⁃58.
［32］	Hadeler E, Mosca M, Hong J, et al. Nail psoriasis: a review of effective therapies and recommendations for management［J］. Dermatol Ther（Heidelb）, 2021,11（3）:799⁃831. doi: 10.1007/s13555⁃021⁃00523⁃x.
［33］	Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate⁃to⁃severe psoriasis［J］. J Eur Acad Dermatol Venereol, 2009,23（8）:896⁃904. doi: 10.1111/j.1468⁃3083.2009. 03211.x.
［34］	Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate⁃to⁃severe psoriasis: a retrospective analysis of the EXPRESS Trial［J］. Dermatology, 2010,221（2）:172⁃178. doi: 10.1159/000317 775.
［35］	Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase⁃3, randomized, placebo⁃controlled trial［J］. J Eur Acad Dermatol Venereol, 2019,33（11）:2168⁃2178. doi: 10.1111/jdv.15793.
［36］	Al⁃Mutairi N, Nour T, Al⁃Rqobah D. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing etanercept, infliximab and adalimumab［J］. Expert Opin Biol Ther, 2013,13（5）:625⁃629. doi:10.1517/14712598.2013.783561.
［37］	Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5⁃year results from the randomized placebo⁃controlled TRANSFIGURE study ［J］. Br J Dermatol, 2021,184（3）:425⁃436. doi: 10.1111/bjd. 19262.
［38］	Wasel N, Thaci D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate⁃to⁃severe psoriasis: 52⁃week results from a phase 3, head⁃to⁃head study（IXORA⁃S）［J］. Dermatol Ther（Heidelb）, 2020,10（4）:663⁃670. doi: 10.1007/s13555⁃020⁃00383⁃x.
［39］	Blauvelt A, Leonardi C, Elewski B, et al. A head⁃to⁃head comparison of ixekizumab vs. guselkumab in patients with moderate⁃to⁃severe plaque psoriasis: 24⁃week efficacy and safety results from a randomized, double⁃blinded trial［J］. Br J Dermatol, 2021,184（6）:1047⁃1058. doi: 10.1111/bjd.19509.
［40］	Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:397⁃402. doi: 10. 1111/jdv.14738.
［41］	Merola JF, Elewski B, Tatulych S, et al. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52⁃week, randomized, controlled phase 3 studies in patients with moderate⁃to⁃severe plaque psoriasis［J］. J Am Acad Dermatol, 2017,77（1）:79⁃87. e71. doi: 10.1016/j.jaad.2017.01.053.
［42］	Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails［J］. Dermatol Ther, 2018,31（3）:e12589. doi: 10.1111/dth.12589.
［43］	Shah S, Nikam B, Kale M, et al. Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: a hospital based prospective investigator blind randomized controlled comparative study［J］. Dermatol Ther, 2021,34（1）:e14650. doi: 10.1111/dth.14650.
［44］	Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo⁃controlled, double⁃blind trial［J］. Arch Dermatol, 2011,147（4）:429⁃436. doi: 10.1001/archdermatol. 2010.384.
［45］	Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis and non⁃pustular palmoplantar involvement: results from three phase 3 trials（UNCOVER⁃1, UNCOVER⁃2 and UNCOVER⁃3）［J］. J Eur Acad Dermatol Venereol, 2017,31（10）:1686⁃1692. doi: 10.1111/jdv.14237.
［46］	Gottlieb AB, Kubanov A, Van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate⁃to⁃severe palmoplantar psoriasis: 2.5⁃year results from GESTURE, a randomized, double⁃blind, placebo⁃controlled trial［J］. Br J Dermatol, 2020,182（4）:889⁃899. doi: 10.1111/bjd.18331.
［47］	Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial［J］. J Am Acad Dermatol, 2017,76（1）:70⁃80. doi: 10.1016/j.jaad.2016.07.058.
［48］	Reolid A, Armesto S, Sahuquillo⁃Torralba A, et al. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting［J］. J Am Acad Dermatol, 2022,87（3）:705⁃709. doi: 10. 1016/j.jaad.2022.05.047.
［49］	Megna M, Tommasino N, Potestio L, et al. Real⁃world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28⁃week retrospective study［J］. J Dermatolog Treat, 2022,33（6）:2813⁃2820. doi: 10. 1080/09546634.2022.2081655.
［50］	Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase⁃4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR⁃005 and phase Ⅲ efficacy and safety trial evaluating the effects of apremilast in psoriasis（ESTEEM） clinical trials in patients with moderate to severe psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:99⁃105. doi: 10.1016/j.jaad.2016.02.1164.
［51］	Spencer RK, Elhage KG, Jin JQ, et al. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta⁃analysis［J］. Dermatol Ther（Heidelb）, 2023,13（2）:437⁃451. doi: 10.1007/s13555⁃022⁃00877⁃w.
［52］	Ioannides D, Antonakopoulos N, Chasapi V, et al. A real⁃world, non⁃interventional, prospective study of the effectiveness and safety of apremilast in bio⁃naive adults with moderate plaque psoriasis treated in the routine care in Greece ⁃ the ′APRAISAL′ study［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:2055⁃2063. doi:10.1111/jdv.18166.
［53］	Hong JJ, Mosca ML, Hadeler EK, et al. Genital and inverse/intertriginous psoriasis: an updated review of therapies and recommendations for practical management［J］. Dermatol Ther（Heidelb）, 2021,11（3）:833⁃844. doi: 10.1007/s13555⁃021⁃00536⁃ 6.
［54］	Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double⁃blinded, placebo⁃controlled phase Ⅲb study of patients with moderate⁃to⁃severe genital psoriasis［J］. Br J Dermatol, 2018,179（4）:844⁃852. doi: 10. 1111/bjd.16736.
［55］	Guenther L, Potts Bleakman A, Weisman J, et al. Ixekizumab results in persistent clinical improvement in moderate⁃to⁃severe genital psoriasis during a 52 week, randomized, placebo⁃controlled, phase 3 clinical trial［J］. Acta Derm Venereol, 2020, 100（1）: adv00006. doi:10.2340/00015555⁃3353.

[1]	Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578.
[2]	Wang Yukun, Liu Jie. Application of deep learning in non-neoplastic dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220660-e20220660.
[3]	Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865.
[4]	Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394.
[5]	Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448.
[6]	Wang Shiqi, Wang Aiping, Li Hang, Li Ruoyu. Comparison of dermoscopic features of toenail psoriasis and fingernail psoriasis [J]. Chinese Journal of Dermatology, 2024, 57(2): 161-165.
[7]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848.
[8]	Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844.
[9]	Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802.
[10]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[11]	Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.
[12]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[13]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[14]	China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401.
[15]	Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes [J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368.

Systemic treatment options for psoriasis in special areas

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［55］

Related Articles 15

Metrics

Comments

Recommended 10